Study of Telitacicept in Patients With Refractory IgA Nephropathy

Status Not yet recruiting

Clinical Trial Summary

The goal of this clinical trial is to explore the effectiveness and safety of Telitacicept in adults with refractory IgA nephropathy. The main questions it aims to answer are: - To evaluate the clinical efficacy of Telitacicept in patients with refractory IgA nephropathy. - To evaluate the safety and adverse reaction of Telitacicept in patients with refractory IgA nephropathy. Participants will be subcutaneously injected with 240mg of Telitacicept once per week. Study subject: After 6 months of sequential treatment with renin-angiotensin system (RAS) blockers or glucocorticoids, patients with pathological biopsy of 0.7≥5 g/24 hours of proteinuria was confirmed as refractory IgA nephropathy.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05596708
Study type	Interventional
Source	Second Affiliated Hospital, School of Medicine, Zhejiang University
Contact
Status	Not yet recruiting
Phase	Phase 2/Phase 3
Start date	March 1, 2023
Completion date	September 30, 2026

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05016323` - A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Primary IgA Nephropathy.	Phase 2
Withdrawn	`NCT02433236` - Open Label Study of Fostamatinib in the Treatment of IgA Nephropathy	Phase 2
Recruiting	`NCT02231125` - Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy	Phase 4
Completed	`NCT01502579` - An Observational Study of IgA Nephropathy: Pathological Variants and Clinical Data	N/A
Not yet recruiting	`NCT01203007` - Diet Intervention in Food Sensitive Patients With IgA Nephropathy	N/A
Terminated	`NCT01129557` - Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease	Phase 4
Completed	`NCT00657059` - Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy (IgAN)	Phase 3
Recruiting	`NCT04684745` - Open-Label Extension Study of BION-1301 in IgA Nephropathy	Phase 2
Completed	`NCT03719443` - First in Human Study to Assess Safety of VIS649 in Healthy Subjects	Phase 1
Withdrawn	`NCT02052219` - BRILLIANT-SC: A Study of the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy	Phase 3
Completed	`NCT02112838` - Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy	Phase 2
Completed	`NCT00767221` - Oral Treatment With PL-56 in Patients With IgA Nephropathy - an Explorative Study	Phase 2
Recruiting	`NCT04438603` - The Applicaiton of Immune Repertoire in the Diagnosis and Disease Monitoring of IgA Nephropathy
Recruiting	`NCT06065852` - National Registry of Rare Kidney Diseases
Terminated	`NCT04905212` - A Study of Telitacicept for Injection (RC18) in Subjects With IgA Nephropathy	Phase 2
Terminated	`NCT04042623` - Study of Safety and Efficacy of AVB-S6-500 in Patients With IgA Nephropathy	Phase 2
Recruiting	`NCT03633864` - Fecal Microbiota Transplantation for Refractory IgA Nephropathy	Phase 2
Recruiting	`NCT02954419` - IgA Nephropathy Biomarkers Evaluation Study (INTEREST)
Recruiting	`NCT03001947` - IgA Nephropathy Registration Initiative of High Quality (INSIGHT)
Completed	`NCT01224028` - A Study to Evaluate the Efficacy and Safety of Tacrolimus in Korean Nephropathy Patients	Phase 2